| Literature DB >> 19562257 |
Adelheid Wöhrer1,2, Thomas Waldhör3, Harald Heinzl4, Monika Hackl5, Johann Feichtinger6, Ulrike Gruber-Mösenbacher7, Andreas Kiefer8, Hans Maier9, Reinhard Motz10, Angelika Reiner-Concin11, Bernd Richling12, Carmen Idriceanu13, Michael Scarpatetti14, Roland Sedivy15, Hans-Christian Bankl15, Wolfgang Stiglbauer16, Matthias Preusser17, Karl Rössler18, Johannes Andreas Hainfellner19,20.
Abstract
In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported. The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for the registration of malignant and non-malignant brain tumours. All Austrian neuropathology units involved in brain tumour diagnostics contribute data on primary brain tumours. Non-microscopically verified cases are added by the Austrian National Cancer Registry to ensure a population-based dataset. In 2005, we registered a total of 1,688 newly diagnosed primary brain tumours in a population of 8.2 million inhabitants with an overall age-adjusted incidence rate of 18.1/100,000 person-years. Non-malignant cases constituted 866 cases (51.3%). The incidence rate was higher in females (18.6/100,000) as compared to males (17.8/100,000), while 95/1,688 (5.6%) cases were diagnosed in children (<18 years). The most common histology was meningioma (n = 504, 29.9%) followed by glioblastoma (n = 340, 20.1%) and pituitary adenoma (n = 151, 8.9%). Comparison with the Central Brain Tumor Registry of the United States (CBTRUS) database showed high congruency of findings. The ABTR model led by neuropathologists in collaboration with epidemiologists and the Austrian National Cancer Registry presents a cooperative way to establish a population-based brain tumour registry with high quality data. This setting links cancer registration to the mission of medical practice and research as defined by the World Medical Association in the Declaration of Helsinki. The continued operation of ABTR will aid in monitoring changes in incidence and in identifying regional disease clusters or geographic variations in brain tumour morbidity/mortality.Entities:
Mesh:
Year: 2009 PMID: 19562257 DOI: 10.1007/s11060-009-9938-9
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.130